Ken Griffin Oncocyte Corp Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.2 - $0.35 $2,020 - $3,535
10,100 New
10,100 $2,000
Q3 2022

Nov 14, 2022
SELL
$0.76 - $15.98 $37,316 - $784,618
-49,100 Reduced 66.35%
24,900 $18,000

Others Institutions Holding OCX

# of Institutions
3
Shares Held
411K
Call Options Held
0
Put Options Held
0
View Full List

About Oncocyte Corp

OCX Quotes by TradingView
  • Ticker OCX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,609,000
  • Market Cap $260M
  • Description
  • OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....
More about OCX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email